Beta
Back to RXRX.US Analysis

Ticker

Value

empty

There is no following symbol in this watchlist.

  • EPS
  • EPS Diluted
  • Revenue
  • Operation Income
  • Net Income
  • Operating Expenses
  • Cash Flow
  • Cash & Debt
  • Current Contract Liabilities
eps-diluted-chart

RXRX EPS Diluted

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

The latest data point for RXRX's EPS Diluted in Q4'25 shows a value of -0.17 USD, marking a notable improvement from the previous quarter's -0.36 USD and representing the least negative figure in the observed period from Q1'23 to Q4'25. Over the full timeframe, EPS Diluted exhibited a generally declining trend through 2023 and much of 2024, with values worsening from -0.34 USD in Q1'23 to a low of -0.57 USD in Q4'24, reflecting ongoing operational losses typical in the biotech sector. However, a recovery emerged in 2025, with EPS improving progressively to -0.17 USD by Q4'25, supported by positive year-over-year growth of 70.2% in that quarter after earlier volatility, including a brief uptick in Q3'24. This suggests stabilizing fundamentals, though the company remains unprofitable overall.